131 related articles for article (PubMed ID: 29260831)
1. Comparative stability, toxicity and anti-leishmanial activity of triphenyl antimony(v) and bismuth(v) α-hydroxy carboxylato complexes.
Duffin RN; Blair VL; Kedzierski L; Andrews PC
Dalton Trans; 2018 Jan; 47(3):971-980. PubMed ID: 29260831
[TBL] [Abstract][Full Text] [Related]
2. Comparative stability, cytotoxicity and anti-leishmanial activity of analogous organometallic Sb(V) and Bi(V) acetato complexes: Sb confirms potential while Bi fails the test.
Duffin RN; Blair VL; Kedzierski L; Andrews PC
J Inorg Biochem; 2018 Dec; 189():151-162. PubMed ID: 30267965
[TBL] [Abstract][Full Text] [Related]
3. Stability and toxicity of tris-tolyl bismuth(V) dicarboxylates and their biological activity towards Leishmania major.
Ong YC; Blair VL; Kedzierski L; Tuck KL; Andrews PC
Dalton Trans; 2015 Nov; 44(41):18215-26. PubMed ID: 26425978
[TBL] [Abstract][Full Text] [Related]
4. Structural influences on the activity of bismuth(III) indole-carboxylato complexes towards Helicobacter pylori and Leishmania.
Pathak A; Blair VL; Ferrero RL; Kedzierski L; Andrews PC
J Inorg Biochem; 2017 Dec; 177():266-275. PubMed ID: 28583712
[TBL] [Abstract][Full Text] [Related]
5. Development of new combination anti-leishmanial complexes: Triphenyl Sb(V) mono-hydroxy mono-quinolinolates.
Duffin RN; Blair VL; Kedzierski L; Andrews PC
J Inorg Biochem; 2021 Jun; 219():111385. PubMed ID: 33894637
[TBL] [Abstract][Full Text] [Related]
6. Anti-leishmanial activity and cytotoxicity of a series of tris-aryl Sb(V) mandelate cyclometallate complexes.
Duffin RN; Blair VL; Kedzierski L; Andrews PC
J Inorg Biochem; 2020 Feb; 203():110932. PubMed ID: 31790875
[TBL] [Abstract][Full Text] [Related]
7. Bismuth(III) β-thioxoketonates as antibiotics against Helicobacter pylori and as anti-leishmanial agents.
Andrews PC; Blair VL; Ferrero RL; Junk PC; Kedzierski L; Peiris RM
Dalton Trans; 2014 Jan; 43(3):1279-91. PubMed ID: 24190067
[TBL] [Abstract][Full Text] [Related]
8. Bismuth(III) α-hydroxy carboxylates: highly selective toxicity of glycolates towards Leishmania major.
Loh A; Ong YC; Blair VL; Kedzierski L; Andrews PC
J Biol Inorg Chem; 2015 Oct; 20(7):1193-203. PubMed ID: 26411702
[TBL] [Abstract][Full Text] [Related]
9. Stability and toxicity of heteroleptic organometallic Bi(V) complexes towards Leishmania major.
Ong YC; Blair VL; Kedzierski L; Andrews PC
Dalton Trans; 2014 Sep; 43(34):12904-16. PubMed ID: 25019320
[TBL] [Abstract][Full Text] [Related]
10. Anti-leishmanial activity of heteroleptic organometallic Sb(v) compounds.
Ali MI; Rauf MK; Badshah A; Kumar I; Forsyth CM; Junk PC; Kedzierski L; Andrews PC
Dalton Trans; 2013 Dec; 42(48):16733-41. PubMed ID: 24077559
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and characterization of bismuth(III) and antimony(V) porphyrins: high antileishmanial activity against antimony-resistant parasite.
Gomes ML; DeFreitas-Silva G; dos Reis PG; Melo MN; Frézard F; Demicheli C; Idemori YM
J Biol Inorg Chem; 2015 Jul; 20(5):771-9. PubMed ID: 25929728
[TBL] [Abstract][Full Text] [Related]
12. The thiol-based reduction of Bi(V) and Sb(V) anti-leishmanial complexes.
Duffin RN; Stephens LJ; Blair VL; Kedzierski L; Andrews PC
J Inorg Biochem; 2021 Aug; 221():111470. PubMed ID: 33971522
[TBL] [Abstract][Full Text] [Related]
13. Alkyl gallium(III) quinolinolates: A new class of highly selective anti-leishmanial agents.
Duffin RN; Blair VL; Kedzierski L; Andrews PC
Eur J Med Chem; 2020 Jan; 186():111895. PubMed ID: 31771825
[TBL] [Abstract][Full Text] [Related]
14. Anti-Leishmanial activity of homo- and heteroleptic bismuth(III) carboxylates.
Andrews PC; Frank R; Junk PC; Kedzierski L; Kumar I; MacLellan JG
J Inorg Biochem; 2011 Mar; 105(3):454-61. PubMed ID: 20851471
[TBL] [Abstract][Full Text] [Related]
15. Modulating aryl substitution: Does it play a role in the anti-leishmanial activity of a series of tetra-aryl Sb(V) fluorinated carboxylates?
Artem'eva EV; Duffin RN; Munuganti S; Efremov AN; Andrews PC; Sharutina OK; Sharutin VV
J Inorg Biochem; 2022 Sep; 234():111864. PubMed ID: 35636013
[TBL] [Abstract][Full Text] [Related]
16. Homo- and heteroleptic bismuth(III/V) thiolates from N-heterocyclic thiones: synthesis, structure and anti-microbial activity.
Luqman A; Blair VL; Brammananth R; Crellin PK; Coppel RL; Andrews PC
Chemistry; 2014 Oct; 20(44):14362-77. PubMed ID: 25224757
[TBL] [Abstract][Full Text] [Related]
17. Do bismuth complexes hold promise as antileishmanial drugs?
Ong YC; Kedzierski L; Andrews PC
Future Med Chem; 2018 Jul; 10(14):1721-1733. PubMed ID: 29961352
[TBL] [Abstract][Full Text] [Related]
18. Improved antileishmanial activity of Dppz through complexation with antimony(III) and bismuth(III): investigation of the role of the metal.
Lizarazo-Jaimes EH; Monte-Neto RL; Reis PG; Fernandes NG; Speziali NL; Melo MN; Frézard F; Demicheli C
Molecules; 2012 Oct; 17(11):12622-35. PubMed ID: 23099618
[TBL] [Abstract][Full Text] [Related]
19. Chemistry and Some Biological Potential of Bismuth and Antimony Dithiocarbamate Complexes.
Adeyemi JO; Onwudiwe DC
Molecules; 2020 Jan; 25(2):. PubMed ID: 31940910
[TBL] [Abstract][Full Text] [Related]
20. Novel antimony(iii) hydroxamic acid complexes as potential anti-leishmanial agents.
Keogan DM; Oliveira SSC; Sangenito LS; Branquinha MH; Jagoo RD; Twamley B; Santos ALS; Griffith DM
Dalton Trans; 2018 May; 47(21):7245-7255. PubMed ID: 29757339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
